COMMERCIAL EXPLOITATION AGREEMENTCommercial Exploitation Agreement • May 23rd, 2023 • Indivior PLC • Pharmaceutical preparations • Delaware
WHEREAS, RB wishes to engage MSX to manufacture and supply the Products (as defined below) on the terms of this Agreement and MSX wishes to manufacture and supply the Products to RB on the terms of this Agreement.
DATED AUGUST 15, 2008Commercial Exploitation Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
WHEREAS, RB wishes to engage MSX to manufacture and supply the Products (as defined below) on the terms of this Agreement and MSX wishes to manufacture and supply the Products to RB on the terms of this Agreement.
AGREEMENTCommercial Exploitation Agreement • June 27th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement (this “Agreement”), dated as of September 24, 2017, is by and between MonoSol Rx, LLC, a Delaware limited liability company (“MonoSol”); and Indivior Inc., a Delaware corporation, and Indivior UK Limited, a corporation organized under the laws of England and Wales, as successors in interest to Reckitt Benckiser Pharmaceuticals Inc. and RB Pharmaceuticals Limited, respectively (collectively, “Indivior”).
THE SYMBOL “[****]” DENOTES PLACES WHERE CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH (i) NOT MATERIAL, AND (ii) WOULD LIKELY CAUSE COMPETITIVE HARM TO THE COMPANY IF PUBLICLY DISCLOSED. AMENDMENT NO. 11 TO...Commercial Exploitation Agreement • March 31st, 2023 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations
CEL AGREEMENT No CEA/0580/11/12Commercial Exploitation Agreement • September 17th, 2020 • England
This AGREEMENT is made the .................. day of ............... two thousand and eleven BETWEEN THE SECRETARY OF STATE FOR DEFENCE (hereinafter called 'the Ministry') of the one part and General Dynamics United Kingdom Limited whose registered office is situated at Bryn Brithdir Oakdale Business Park Blackwood South Wales NP12 4AA (hereinafter called 'the Contractor' which expression where the context so admits or requires shall include its successors in title) of the other part.
THIS EXHIBIT HAS BEEN REDACTED AND IS THE SUBJECT OF A CONFIDENTIAL TREATMENT REQUEST. REDACTED MATERIAL IS MARKED WITH [***] AND HAS BEEN FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION.Commercial Exploitation Agreement • July 16th, 2018 • Aquestive Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Agreement (this “Agreement”), dated as of September 24, 2017, is by and between MonoSol Rx, LLC, a Delaware limited liability company (“MonoSol”); and Indivior Inc., a Delaware corporation, and Indivior UK Limited, a corporation organized under the laws of England and Wales, as successors in interest to Reckitt Benckiser Pharmaceuticals Inc. and RB Pharmaceuticals Limited, respectively (collectively, “Indivior”).
